ValuEngine upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a buy rating in a research report released on Thursday morning, ValuEngine reports.
Several other analysts also recently commented on COLL. Needham & Company LLC lowered their target price on shares of Collegium Pharmaceutical from $33.00 to $25.00 and set a buy rating for the company in a report on Wednesday, October 30th. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a hold rating to a sell rating in a report on Thursday, November 7th. William Blair reiterated a buy rating on shares of Collegium Pharmaceutical in a report on Tuesday, September 17th. Jefferies Financial Group increased their target price on shares of Collegium Pharmaceutical from $26.00 to $36.00 in a report on Thursday, November 7th. Finally, SunTrust Banks increased their target price on shares of Collegium Pharmaceutical to $22.00 and gave the company a buy rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $24.57.
Shares of Collegium Pharmaceutical stock traded up $0.75 during trading hours on Thursday, reaching $18.86. The company’s stock had a trading volume of 302,600 shares, compared to its average volume of 380,309. Collegium Pharmaceutical has a one year low of $10.01 and a one year high of $19.99. The company has a market capitalization of $613.21 million, a P/E ratio of -15.85 and a beta of 0.52. The stock’s fifty day simple moving average is $13.50 and its two-hundred day simple moving average is $12.26. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.20 and a current ratio of 1.24.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). The firm had revenue of $72.94 million during the quarter, compared to analysts’ expectations of $74.32 million. Collegium Pharmaceutical had a negative net margin of 3.86% and a negative return on equity of 13.14%. The business’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.50) EPS. As a group, research analysts forecast that Collegium Pharmaceutical will post -0.64 earnings per share for the current year.
In related news, Director David Hirsch sold 22,106 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $11.65, for a total transaction of $257,534.90. Following the completion of the sale, the director now owns 64,223 shares in the company, valued at $748,197.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Joseph Ciaffoni sold 64,821 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $18.77, for a total transaction of $1,216,690.17. Following the sale, the chief executive officer now owns 242,276 shares of the company’s stock, valued at approximately $4,547,520.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 111,927 shares of company stock valued at $1,957,475. 8.08% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. First Quadrant L P CA increased its stake in shares of Collegium Pharmaceutical by 87.2% in the second quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock worth $59,000 after purchasing an additional 2,089 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of Collegium Pharmaceutical by 33.0% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 6,041 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 1,500 shares in the last quarter. Meeder Asset Management Inc. increased its stake in shares of Collegium Pharmaceutical by 1,299.5% in the third quarter. Meeder Asset Management Inc. now owns 8,495 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 7,888 shares in the last quarter. Nisa Investment Advisors LLC purchased a new position in shares of Collegium Pharmaceutical in the third quarter worth about $98,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Collegium Pharmaceutical in the third quarter worth about $116,000. Institutional investors and hedge funds own 91.31% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Featured Story: Most Active Stocks: Dollar Volume vs Share Volume
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.